Smart Health Application for Remote Tracking of Ambulatory Patients

2021 ◽  
pp. 33-55
Author(s):  
Shariq Aziz Butt ◽  
Muhammad Waqas Anjum ◽  
Syed Areeb Hassan ◽  
Arindam Garai ◽  
Edeh Michael Onyema
2018 ◽  
Vol 5 (2) ◽  
pp. 614-623 ◽  
Author(s):  
Jaganathan Venkatesh ◽  
Baris Aksanli ◽  
Christine S. Chan ◽  
Alper Sinan Akyurek ◽  
Tajana Simunic Rosing

2021 ◽  
Vol 10 (1) ◽  
pp. 72
Author(s):  
Du'a Alzaleq ◽  
Suboh Alkhushayni ◽  
Austin FitzGerald

This paper describes HealthTracker, a mobile health application to record, store, display, and analyze personal health data. This application allows an individual to log several types of data encompassing their personal health. HealthTracker serves as a model for both a recording and a recommending system. Its goal is to serve as a bridge for future personal health systems to build from. A person’s health information is displayed in an easy-to-understand manner but is also practical for medical professionals. Users should find the system useful and effective no matter if they use it simply or extensively. Currently, the system serves as a prototype for determining the practical applications for smart health systems running on mobile platforms.  


1992 ◽  
Vol 31 (01) ◽  
pp. 18-28 ◽  
Author(s):  
C. Combi ◽  
G. Pozzi ◽  
R. Rossi ◽  
F. Pinciroli

Abstract:Many clinics are interested to use software packages in daily practice, but lack of integration of such packages seriously limits their scope. In practice this often entails switching between programs and interrupting the run of an individual program. A multi-task approach would not solve this problem as it would not eliminate the need to input the same data many times, as often occurs when using separate packages. The construction of a Multi-Service Medical Software package (MSx2) is described, which was also developed as an example of practical integration of some clinically relevant functions. The package runs on a personal computer in an MS-DOS environment and integrates a time-oriented medical record management unit (TOMRU) for data of ambulatory patients, and a drug information management unit (DIMU) concerning posology, content, effects, and possible interactions. Of the possible database configurations allowed by MSx2, the cardiology patient database (MSx2/C) and hypertensive patient database (MSx2/H) were developed and described here. Clinical information to be included in the configurations was obtained after discussion and consensus of clinical practitioners. MSx2/C was distributed to several hundred clinical centers during computerized courses to train future users. MSx2 can easily transfer patient data to statistical processing packages.


1996 ◽  
Vol 76 (06) ◽  
pp. 0939-0943 ◽  
Author(s):  
B Boneu ◽  
G Destelle ◽  

SummaryThe anti-aggregating activity of five rising doses of clopidogrel has been compared to that of ticlopidine in atherosclerotic patients. The aim of this study was to determine the dose of clopidogrel which should be tested in a large scale clinical trial of secondary prevention of ischemic events in patients suffering from vascular manifestations of atherosclerosis [CAPRIE (Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events) trial]. A multicenter study involving 9 haematological laboratories and 29 clinical centers was set up. One hundred and fifty ambulatory patients were randomized into one of the seven following groups: clopidogrel at doses of 10, 25, 50,75 or 100 mg OD, ticlopidine 250 mg BID or placebo. ADP and collagen-induced platelet aggregation tests were performed before starting treatment and after 7 and 28 days. Bleeding time was performed on days 0 and 28. Patients were seen on days 0, 7 and 28 to check the clinical and biological tolerability of the treatment. Clopidogrel exerted a dose-related inhibition of ADP-induced platelet aggregation and bleeding time prolongation. In the presence of ADP (5 \lM) this inhibition ranged between 29% and 44% in comparison to pretreatment values. The bleeding times were prolonged by 1.5 to 1.7 times. These effects were non significantly different from those produced by ticlopidine. The clinical tolerability was good or fair in 97.5% of the patients. No haematological adverse events were recorded. These results allowed the selection of 75 mg once a day to evaluate and compare the antithrombotic activity of clopidogrel to that of aspirin in the CAPRIE trial.


Sign in / Sign up

Export Citation Format

Share Document